`
`In re application of:
`
`Purdue Pharma L. P.
`
`Confirmation No.: 8650
`
`Art Unit: 1628
`
`Appl. No.: 15/442,231
`
`Examiner: Ricci, Craig D.
`
`Filed: February 24, 2017
`
`Atty. Docket: 1861.2700005/JMC/MSB
`
`For: Buprenorphine-Wafer for Drug
`
`Substitution Therapy
`
`Statement on Substance of Interview
`
`Commissioner for Patents
`
`PO Box 1450
`
`Alexandria, VA 22313-1450
`
`Mail Stop RCE
`
`This paper is being filed in light of a telephonic interview between the Examiner and
`
`Applicant's representative on July 18, 2018. The Office is authorized to charge any fees that may be
`
`due with this paper, or credit any overpayments, to Deposit Account No. 19-0036.
`
`Remarks begin on page 2.
`
`
`
`Purdue Pharma L. P.
`
`Appl. No. 15/442,231
`
`Statement on Substance of Interview
`
`Remarks
`
`On July 18, 2018, Applicant's representative, Matthew Bodenstein, conducted a telephonic
`
`interview with the Examiner regarding the outstanding 35 U.S.C. § 112 rejection. During the
`
`interview, Applicant's representative and the Examiner discussed the possibility of excluding certain
`
`antagonists from the claim. The Examiner indicated that an amendment of this nature would likely
`
`be sufficient to overcome the pending § 112 rejection. Applicant's representative thanks the
`
`Examiner for his time.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & Fox P.L.L.C.
`
`/Matthew S. Bodenstein/
`
`Matthew S. Bodenstein
`
`Registration No. 58,885
`
`Date: August 10, 2018
`
`1100 New York Avenue, NW.
`Washington, DC. 20005-3934
`(202) 371-2600
`
`979916471
`
`Atty. Dkt. No.:
`1861.2700005/JMC/MSB
`
`